Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576 584. doi: 613. Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D Angelo A, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphos- pholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848 853. doi: 614. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the an- tiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133 1138. 615. Okuma H, Kitagawa Y, Yasuda T, Tokuoka K, Takagi S. Comparison be- tween single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke pa- tients with antiphospholipid syndrome. Int J Med Sci. 2009;7:15 18. doi: 616. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365 1371. 617. Ordi-Ros J, S ez-Comet L, P rez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salom A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Sol C, et al. Rivaroxaban versus vitamin K antagonist in antiphospho- lipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019; 618. Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, Salta S, Gerotziafas G, Jing ZC, Elalamy I, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants: results from an international patient-level data meta-analysis. Autoimmun 619. 